Murayama Anju, Shigeta Haruki, Kamamoto Sae, Yamashita Erika, Saito Hiroaki, Sawano Toyoaki, Bhandari Divya, Shrestha Sunil, Kusumi Eiji, Tanimoto Tetsuya, Ozaki Akihiko
Medical Governance Research Institute Minato-ku Tokyo Japan.
School of Medicine Tohoku University Sendai city Miyagi Japan.
OTO Open. 2023 Feb 17;7(1):e31. doi: 10.1002/oto2.31. eCollection 2023 Jan-Mar.
To evaluate the magnitude, prevalence, and trend of the financial relationship between Japanese head and neck surgeons and pharmaceutical companies between 2016 and 2019.
Cross-sectional analysis.
Japan.
This study evaluated personal payments concerning lecturing, consulting, and writing paid by 92 major pharmaceutical companies to all Japanese head and neck surgeons board-certified by the Japan Society for Head and Neck Surgery between 2016 and 2019. The payments were descriptively analyzed and payment trend were assessed using population-averaged generalized estimating equations. Further, the payments to board executive board members with specialist certification were also evaluated separately.
Of all 443 board-certified head and neck surgeons in Japan, 365 (82.4%) received an average of $6443 (standard deviation: $12,875), while median payments were $2002 (interquartile ranges [IQR] $792-$4802). Executive board specialists with a voting right received much higher personal payments (median $26,013, IQR $12,747-$35,750) than the non-executive specialists (median $1926, IQR $765‒$4134, < .001) and the executive board specialists without a voting right (median $4411, IQR $963-$5623, = .015). The payments per specialist and prevalence of specialists with payments annually increased by 11.4% (95% CI: 5.8%-17.2%; < .001) and 7.3% (95% CI: 3.8%-11.0%; < .001), respectively.
There were increasingly widespread and growing financial relationships with pharmaceutical companies among head and neck surgeons in Japan, alongside of introduction of novel drugs. The leading head and neck surgeons received much higher personal payments from pharmaceutical companies, and no sufficient regulation was implemented by the society in Japan.
评估2016年至2019年间日本头颈外科医生与制药公司之间财务关系的规模、普遍性和趋势。
横断面分析。
日本。
本研究评估了2016年至2019年间92家主要制药公司向所有获得日本头颈外科学会认证的日本头颈外科医生支付的有关讲学、咨询和写作的个人报酬。对这些报酬进行描述性分析，并使用总体平均广义估计方程评估报酬趋势。此外，还分别评估了向具有专科认证的董事会执行委员会成员的报酬。
在日本所有443名获得认证的头颈外科医生中，365名（82.4%）平均获得6443美元（标准差：12875美元），而报酬中位数为2002美元（四分位间距[IQR]为792 - 4802美元）。拥有投票权的执行委员会专科医生获得的个人报酬（中位数26013美元，IQR为12747 - 35750美元）远高于非执行专科医生（中位数1926美元，IQR为765 - 4134美元，P <.001）和没有投票权的执行委员会专科医生（中位数4411美元，IQR为963 - 5623美元，P = 0.015）。每位专科医生的报酬以及获得报酬的专科医生的普遍性每年分别增长11.4%（95%置信区间：5.8% - 17.2%；P <.001）和7.3%（95%置信区间：3.8% - 11.；P <.001）。
在日本，随着新药的推出，头颈外科医生与制药公司之间的财务关系日益广泛且不断增长。主要的头颈外科医生从制药公司获得的个人报酬要高得多，而日本的学会并未实施充分的监管。
